EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer

Xinghao Ai, Renhua Guo, Liang Zhang, Jian Fang, Yiping Zhang, Jianhua Chen, Jun Zhao, Feng Ye, Shumei Wang, Meiqi Shi, Xinwei Zhang, Fang Zhang und 7 weitere

European Journal of Cancer · 2026-02 · 235 · 116221

DOI: 10.1016/j.ejca.2026.116221 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-02. Verfasst von Xinghao Ai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of M…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansAnaplastic Lymphoma KinaseMaleFemaleAnimalsMiddle AgedAgedAdultMaximum Tolerated DoseXenograft Model Antitumor AssaysReceptor Protein-Tyrosine KinasesMiceCell Line, TumorProtein-Tyrosine KinasesGene RearrangementAged, 80 and overDose-Response Relationship, DrugProto-Oncogene Proteins

Stichwörter der Autor:innen

ALKDirozalkibEfficacyNon-small cell lung cancerPharmacokineticsPhase ISafety

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesAntineoplastic AgentsProtein-Tyrosine KinasesROS1 protein, humanProto-Oncogene Proteins

Autor:innen und Institutionen

  • Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Oncology, Jilin Cancer Hospital, Changchun, China.
  • Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Internal Thoracic Medicine, Hunan Cancer Hospital, Changsha, China.

Zitieren

APA

Ai, X., Guo, R., Zhang, L., Fang, J., Zhang, Y., Chen, J., Zhao, J., Ye, F., Wang, S., Shi, M., Zhang, X., Zhang, F., Li, J., Wang, L., Guo, X., Xu, L., Duan, X., Hu, Y., & Lu, S. (2026). Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European Journal of Cancer, 235, 116221. https://doi.org/10.1016/j.ejca.2026.116221

Vancouver

Ai X, Guo R, Zhang L, Fang J, Zhang Y, Chen J, et al. Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European Journal of Cancer. 2026;235:116221. doi:10.1016/j.ejca.2026.116221

BibTeX
@article{Ai2026,
  author = {Ai, Xinghao and Guo, Renhua and Zhang, Liang and Fang, Jian and Zhang, Yiping and Chen, Jianhua and Zhao, Jun and Ye, Feng and Wang, Shumei and Shi, Meiqi and Zhang, Xinwei and Zhang, Fang and Li, Jiakui and Wang, Li and Guo, Xuejie and Xu, Lingmei and Duan, Xianghui and Hu, Yan and Lu, Shun},
  title = {Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {235},
  pages = {116221},
  doi = {10.1016/j.ejca.2026.116221}
}
Kostenlos starten →